Navidea Biopharmaceuticals (NYSE: NAVB) reported Q2 EPS of ($0.07), in-line with the analyst estimate of ($0.07). Revenue for the quarter came in at $1.1 million versus the consensus estimate of $1.08 million.

For earnings history and earnings-related data on Navidea Biopharmaceuticals (NAVB) click here.